January 9, 2017
We closed 2016 with the submission of our first NDA for ITCA 650 in T2D, earning yet another $100M milestone payment from our 2015 Royalty financing.
Between debt, our Series EE equity financing, and the royalty milestone payment we secured nearly $600M in capital in 2016. We have a 3rd and final close of our Series EE round planned in 1Q 2017.
We just signed a major strategic partnership with the Bill and Melinda Gates Foundation aiming our Medici technology at preventing HIV. Novel Medici treatments and preventions: Our vision is in motion!
In 2017 we are focused on scaling the business and driving robust execution as we work with global health authorities and fully prepare to bring our first medicine to patients with type 2 diabetes.
Chairman & CEO Kurt Graves Explains the Vision and Culture of Intarcia
What immediately sets Intarcia apart from other companies is what’s most visible – our product candidate that is built on amazing technology and chemistry. But what most outsiders cannot see is even more amazing – our people and our culture. Our people have a will to win. They are not intimidated by the skeptics who doubt that a relatively small biotech can change the course of treatment in serious disease. They say, "Watch us!"